ArticleNature communications2026

Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial.

Pin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.